Source: Zolmax News

Leap Therapeutics: Leap Therapeutics Inc (NASDAQ:LPTX) Expected to Announce Earnings of -$0.17 Per Share

Brokerages forecast that Leap Therapeutics Inc (NASDAQ:LPTX) will post earnings per share (EPS) of ($0.17) for the current quarter, Zacks reports. Zero analysts have made estimates for Leap Therapeutics' earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.12). Leap Therapeutics reported earnings per share of ($0.33) [...]

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Chris Mirabelli's photo - CEO of Leap Therapeutics

CEO

Chris Mirabelli

CEO Approval Rating

73/100

Leap Therapeutics researches, develops and commercializes monoclonal antibodies that enable immune system to identify and attack cancer cells. Read more